Lifeline Biotechnologies, Inc.'s First Warning System™ in Preparation for Completion in 2008

RENO, Nev.--(BUSINESS WIRE)--Lifeline Biotechnologies, Inc. (Pink Sheets:LLBT) today announced that the Company’s recent meeting with the Managing Engineer of Nanyang Technical University concerning the finalization of the First Warning System™ patient data interpretive software was encouraging. Additional cases of patient data were received, downloaded and reviewed by the development team at the university and the upgrading of the First Warning System™ (FWS) can be accelerated, possibly completing the development by mid 2008.

The new advancements could allow the FWS to classify women who have periodic breast examinations to identify normal, suspicious and positive ranges for breast cancer. The preliminary estimate is that an additional 300 patients will need to be tested and the Company is determining the period of time required to complete this testing. Preliminary estimates by Lifeline’s management suggest the possibility of completion in 2008.

“This is extremely encouraging news. The original estimate was between one and two years to complete the work, but this new update will permit us to conduct the next round of patient testing, possibly in 2008. We expect to be able to use patient test data to support the 510(k) preparation and submission to the FDA,” stated Jim Holmes, CEO of Lifeline Biotechnologies, Inc.

Lifeline recently announced that the Company has been in discussions with various firms to help with the preparation of filing the 510(k) with the FDA. The selected firm will help with the verification and validation guidelines, and the Company expects to announce its selection soon.

About Lifeline Biotechnologies, Inc:

Lifeline Biotechnologies, Inc. is an innovative medical technology company that is focused on completing the development of the First Warning System™, which was designed to assist in the early detection of breast cancer. Of the approximately $138 billion spent on cancer each year, Lifeline could potentially save the healthcare industry up to $4.1 billion annually, assuming the following are successfully completed: the development of the First Warning System™, the completion of clinical trials and FDA pre-marketing clearance. Lifeline competes in the money markets for funds to support the development of its product. The cost of funds, for early stage companies like Lifeline, are expensive and the terms have been, and may continue to be, dilutive.

Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.

Contact:

Lifeline Biotechnologies, Inc.
Investor Relations 
1-886-THE APPL(E)
www.lbti.com